Breast Carcinoma With Unrecognized Neuroendocrine Differentiation Metastasizing to the Pancreas: A Potential Diagnostic Pitfall

Lene Svendstrup Christensen, Michael Bau Mortensen, Sönke Detlefsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The current World Health Organization classification recognizes 3 subtypes of breast carcinomas with neuroendocrine features. Their reported prevalence is highly variable, ranging from <1% to up to 20% of all breast carcinomas. We report the case of a 73-year-old woman who underwent lumpectomy with a postoperative diagnosis of invasive ductal breast carcinoma. Six weeks after lumpectomy, pancreatic biopsies showed tumor cells with neuroendocrine features. The first immunohistochemical panel showed positivity for synaptophysin and cytokeratins, raising suspicion of a pancreatic neuroendocrine tumor. However, a second panel revealed positivity for estrogen receptors and GATA3. On review of the lumpectomy specimen, a significant neuroendocrine component was found, leading to the final diagnosis of breast carcinoma with neuroendocrine features metastasizing to the pancreas. Neuroendocrine markers are not routinely analyzed in breast tumors. Hence, metastases from breast carcinomas with unrecognized neuroendocrine features may lead to false diagnoses of primary neuroendocrine tumors at different metastatic sites, such as the pancreas.

OriginalsprogEngelsk
TidsskriftInternational Journal of Surgical Pathology
Vol/bind24
Udgave nummer5
Sider (fra-til)463-467
ISSN1066-8969
DOI
StatusUdgivet - 2016

Fingeraftryk

Pancreas
Segmental Mastectomy
Neuroendocrine Tumors
Carcinoma, Ductal, Breast
Neuroendocrine Cells
Synaptophysin
Neoplasms

Citer dette

@article{deb1306438a24d01a6ed9f40b52059a2,
title = "Breast Carcinoma With Unrecognized Neuroendocrine Differentiation Metastasizing to the Pancreas: A Potential Diagnostic Pitfall",
abstract = "The current World Health Organization classification recognizes 3 subtypes of breast carcinomas with neuroendocrine features. Their reported prevalence is highly variable, ranging from <1{\%} to up to 20{\%} of all breast carcinomas. We report the case of a 73-year-old woman who underwent lumpectomy with a postoperative diagnosis of invasive ductal breast carcinoma. Six weeks after lumpectomy, pancreatic biopsies showed tumor cells with neuroendocrine features. The first immunohistochemical panel showed positivity for synaptophysin and cytokeratins, raising suspicion of a pancreatic neuroendocrine tumor. However, a second panel revealed positivity for estrogen receptors and GATA3. On review of the lumpectomy specimen, a significant neuroendocrine component was found, leading to the final diagnosis of breast carcinoma with neuroendocrine features metastasizing to the pancreas. Neuroendocrine markers are not routinely analyzed in breast tumors. Hence, metastases from breast carcinomas with unrecognized neuroendocrine features may lead to false diagnoses of primary neuroendocrine tumors at different metastatic sites, such as the pancreas.",
keywords = "Journal Article",
author = "Christensen, {Lene Svendstrup} and Mortensen, {Michael Bau} and S{\"o}nke Detlefsen",
note = "{\circledC} The Author(s) 2016.",
year = "2016",
doi = "10.1177/1066896916632909",
language = "English",
volume = "24",
pages = "463--467",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications",
number = "5",

}

Breast Carcinoma With Unrecognized Neuroendocrine Differentiation Metastasizing to the Pancreas : A Potential Diagnostic Pitfall. / Christensen, Lene Svendstrup; Mortensen, Michael Bau; Detlefsen, Sönke.

I: International Journal of Surgical Pathology, Bind 24, Nr. 5, 2016, s. 463-467.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Breast Carcinoma With Unrecognized Neuroendocrine Differentiation Metastasizing to the Pancreas

T2 - A Potential Diagnostic Pitfall

AU - Christensen, Lene Svendstrup

AU - Mortensen, Michael Bau

AU - Detlefsen, Sönke

N1 - © The Author(s) 2016.

PY - 2016

Y1 - 2016

N2 - The current World Health Organization classification recognizes 3 subtypes of breast carcinomas with neuroendocrine features. Their reported prevalence is highly variable, ranging from <1% to up to 20% of all breast carcinomas. We report the case of a 73-year-old woman who underwent lumpectomy with a postoperative diagnosis of invasive ductal breast carcinoma. Six weeks after lumpectomy, pancreatic biopsies showed tumor cells with neuroendocrine features. The first immunohistochemical panel showed positivity for synaptophysin and cytokeratins, raising suspicion of a pancreatic neuroendocrine tumor. However, a second panel revealed positivity for estrogen receptors and GATA3. On review of the lumpectomy specimen, a significant neuroendocrine component was found, leading to the final diagnosis of breast carcinoma with neuroendocrine features metastasizing to the pancreas. Neuroendocrine markers are not routinely analyzed in breast tumors. Hence, metastases from breast carcinomas with unrecognized neuroendocrine features may lead to false diagnoses of primary neuroendocrine tumors at different metastatic sites, such as the pancreas.

AB - The current World Health Organization classification recognizes 3 subtypes of breast carcinomas with neuroendocrine features. Their reported prevalence is highly variable, ranging from <1% to up to 20% of all breast carcinomas. We report the case of a 73-year-old woman who underwent lumpectomy with a postoperative diagnosis of invasive ductal breast carcinoma. Six weeks after lumpectomy, pancreatic biopsies showed tumor cells with neuroendocrine features. The first immunohistochemical panel showed positivity for synaptophysin and cytokeratins, raising suspicion of a pancreatic neuroendocrine tumor. However, a second panel revealed positivity for estrogen receptors and GATA3. On review of the lumpectomy specimen, a significant neuroendocrine component was found, leading to the final diagnosis of breast carcinoma with neuroendocrine features metastasizing to the pancreas. Neuroendocrine markers are not routinely analyzed in breast tumors. Hence, metastases from breast carcinomas with unrecognized neuroendocrine features may lead to false diagnoses of primary neuroendocrine tumors at different metastatic sites, such as the pancreas.

KW - Journal Article

U2 - 10.1177/1066896916632909

DO - 10.1177/1066896916632909

M3 - Journal article

C2 - 26912472

VL - 24

SP - 463

EP - 467

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 5

ER -